An observational study in Sexually Transmitted Infections (STIs), HIV and PrEP, sponsored by Hospital Universitario de Valme. Recruiting at 26 sites in Spain. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Hospital Universitario de Valme · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Sexually Transmitted Diseases with a site in Spain — 4 open to participants now, 4 under way, none of them phase 3. Sexually Transmitted Diseases · Spain.
Among the 12 studies in Sexually Transmitted Diseases with a site in Spain, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 10th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →4 of the 12 studies in Sexually Transmitted Diseases with a site in Spain are open now. Recruiting first, the newest first:
Parc de Salut Mar · Sites in Spain
Ages 18–25
Hospitales Universitarios Virgen del Rocío · Sites in Spain
Ages 18+ · Healthy volunteers
University of Seville · Sites in Spain
Ages 11–14 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3
First in 2010; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 9,000 is above the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.
Median enrollment 713 across the 6 interventional studies, 766 across the 6 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario de Valme is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Hospital Universitario de Valme has 1 study filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexually Transmitted Diseases with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846241Parc de Salut MarSexual Behavior and Risk Perception as Factors Associated With STI Incidence in Young Adults | 2027-01-15 |
| NCT07208045University of SevilleCultural Adaptation, Validation, and Evaluation of the Programme for Promotion of Healthy Affective-Sexual Behaviours in Adolescents (IYG) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Sexually Transmitted Diseases with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective: To develop and validate a predictive model for acquiring sexually transmitted infections (STIs) in individuals using HIV pre-exposure prophylaxis (PrEP) within the national program providing this strategy.
Methods: Ambispective cohort study, multicentric (23 Spanish hospitals). All PrEP users, with follow-up within the program, will be included. Entry into the program will be considered as the baseline visit. From there, patients are followed quarterly, following the national protocols for monitoring PrEP users in Spain. At each visit, diagnosis of different STIs (serum, pharyngeal swab, urethral or urine sample, rectal swab, endocervical/vaginal swab, ulcer) is performed. Primary outcome variable: development of an STI (Yes/No). The following STIs will be considered: syphilis, Neisseria gonorrhoeae (NG) infection, Chlamydia trachomatis (CT) infection, lymphogranuloma venereum (LGV), Mycoplasma genitalium (MG) infection, genital herpes, hepatitis A, hepatitis B, hepatitis C, HIV infection, and MPOX. Secondary outcome variable: number of diagnosed STIs. In order to determine factors associated with acquiring an STI, multivariate analyses will be conducted using logistic regression. The best models will be analyzed in the validation population. To compare the models, we will follow the Bayesian approach suggested by Benavoli et al.
All individuals who meet the criteria for PrEP use in Spain, are over 16 years old, and have taken at least one pill.
Inclusion Criteria:
The approved criteria for the use of oral PrEP in Spain, as recommended by the Spanish Gesida guidelines (GeSIDA. Recomendaciones sobre la Profilaxis Pre-Exposición para la Prevención de la Infección por VIH en España. Marzo 2023. Available at http://.gesida-seimc.org/category/guias-clinicas/otras-guias-vigentes/), are as follows:
Exclusion Criteria: none
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All individuals with documented initiation of daily oral PrEP, who have collected the medication at least once and have taken at least one pill, will be included in the study. The approved criteria for the use of oral PrEP in Spain, as recommended by the Spanish Gesida guidelines (GeSIDA. Recomendaciones sobre la Profilaxis Pre-Exposición para la Prevención de la Infección por VIH en España. Marzo 2023. Disponible en http://.gesida-seimc.org/category/guias-clinicas/otras-guias-vigentes/), are as follows: * People without HIV infection at the time of cohort inclusion * Age ≥ 16 yr who meet the following criteria: * MSM and transgender women with at least two of the following criteria during the last year: \> 10 sexual partners; Condomless anal sex; Chemsex; PEP; ≥ 1 STI * Sex worker women who report non-habitual use of condoms. * Cisgender males/females, who report condomless and present at least two of the same criteria as MSM and transgender.
Other: No Intervention: Observational Cohort
No Intervention: Observational Cohort
STI predictive model
Predictive model for the acquisition of sexually transmitted infections in individuals using PrEP within the national provision program for this strategy
Time frame: through study completion, an average of 5 years
STI incidence
Incidence of sexually transmitted infections (STIs) in the cohort globally and by type of infection.
Time frame: through study completion, an average of 5 years
STI dynamics
Evolution of STI diagnoses during follow-up among PrEP users included in the study, both globally and by specific pathogen
Time frame: through study completion, an average of 5 years
asymptomatic STIs
Proportion of asymptomatic STIs diagnosed within the screening program.
Time frame: through study completion, an average of 5 years
behavioral changes
Sexual risk behaviors of individuals in the cohort, before and after initiating PrEP
Time frame: through study completion, an average of 5 years
DOXYPEP
Proportion of Individuals who might benefit from the 'Doxy-PEP' strategy (doxycycline use as post-exposure prophylaxis for chlamydia and syphilis)
Time frame: through study completion, an average of 5 years
PrEP discontinuation
Prevalence of oral PrEP discontinuation within a nationwide PrEP users' cohort.
Time frame: through study completion, an average of 5 years
Predictor of PrEP discontinuation
Predictors of oral PrEP discontinuation within a nationwide PrEP users' cohort.
Time frame: through study completion, an average of 5 years
PrEP adherence
Self-reported oral PrEP adherence.
Time frame: through study completion, an average of 5 years
Time to discontinuation
Time elapsed between oral PrEP initiation and oral PrEP discontinuation.
Time frame: through study completion, an average of 5 years
HIV incident infection
Incidence of HIV seroconversions
Time frame: through study completion, an average of 5 years
HIV incident infection
Profiles of those who acquire HIV while taking oral PrEP.
Time frame: through study completion, an average of 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Jan 2025 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.
Of 42 non-industry observational studies under Sexually Transmitted Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 5 months is below that.
Counting every sponsor, half of 48 studies reached it within 26 months; a quarter within 15 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
Hospital Universitario de Valme